Joseph R. Aiello, MD

Education

  • 1996-1998 / University of North Carolina, Chapel Hill, Fellowship, Nephrology 
  • 1995-1996 / University of North Carolina, Chapel Hill, Chief Resident, Internal Medicine
  • 1993-1995 / University of North Carolina, Chapel Hill, Residency, Internal Medicine
  • 1988-1992 / Georgetown University, Doctor of Medicine
  • 1984-1988 / Georgetown University, Bachelor of Science

Work Experience

  • 1998-Present / Clinical Nephrologist, Mountain Kidney and Hypertension Associates, PA
  • 1996-1998 / Fellow in Nephrology, University of North Carolina, Chapel Hill
  • 1993-1996 / Medical Residency, Internal Medicine, University of North Carolina, Chapel Hill

Credentials

  • Medical License: North Carolina Physician License / 9500006
  • Certification: North Carolina Medical Board / 54659
  • American Board of Internal Medicine, 1996, 2006, 2016
  • American Board of Nephrology, 1999, 2008, 2018

Hospital Affiliations

  • 1998-Present
    Mission-St. Joseph's Health System
    509 Biltmore Avenue
    Asheville, NC 28801-4690

Professional Affiliations / Committees

  • Adjunct Professor, Department of Medicine, UNC School of Medicine, Chapel Hill
  • Asheville Specialty Hospital - Medical Executive Committee
  • American Society of Nephrology
  • American Society for Apheresis
  • National Kidney Foundation
  • Renal Physicians Association
  • North Carolina Medical Society

Training

  • National Institutes of Health “Protecting Human Research Participants”
    • 07/13/2009, Certificate #255968
    • 09/26/2012, Certificate #1012544
    • 08/12/2014, Certificate #1516437
  • CITI – Human Research for Biomedical Research Investigators, 09/26/2012, 08/12/2014
  • CITI – Good Clinical Practice, 08/14/2014, 09/06/2016, 11/18/2018

Research

  • Sub-Investigator
    • Trial to Reduce Cardiovascular Events with Aranesp Therapy
  • Principal Investigator
    • A Phase 4, Long-Term Observational Safety Study in End Stage Renal Disease Subjects Treated with Fosrenol
  • Principal Investigator
    • A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using GENZ-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis
  • Principal Investigator
    • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease
  • Principal Investigator
    • A Phase 3, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin
  • Principal Investigator
    • A Phase 3, Randomized, Active-Controlled, Open-Label Study of the Safety and Efficacy of AF37702 Injection for the Correction of Anemia in Patients with Chronic Renal Failure not on Dialysis and not on Erythropoiesis Stimulating Agent (ESA) Treatment
  • Principal Investigator
    • A Randomized Evaluation of the Efficacy and Safety of Ferric Carboxymaltose in Patients with Iron Deficiency Anemia and Impaired Renal Function
  • Principal Investigator
    • A Four Week, Phase IIa, Randomized, double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK1278863 in Subjects with Anemia Associated with Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
  • Principal Investigator
    • A Four-Week, Phase IIa, Randomized, Active-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-Dependent Subjects with Anemia Associated with Chronic Kidney Disease
  • Principal Investigator
    • A Phase II, Randomized, Open-Label, Dose Titration, Efficacy and Safety Study of FGCL-4592 in Non-Dialysis Chronic Kidney Disease Patients with Anemia
  • Principal Investigator
    • An Open-Label, Extension Study to Evaluate the Efficacy and Safety of FGCL-4592 for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients with Chronic Kidney Disease
  • Principal Investigator
    • Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type II Diabetes: The Occurrence of Renal Events (BEACON)
  • Principal Investigator
    • START-CKD: Strategies Using Darbepoetin alfa to Avoid Transfusions in Chronic Kidney Disease
  • Sub-Investigator
    • A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects with Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
  • Sub-Investigator
    • A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects with Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)
  • Principal Investigator
    • Qualitative Interviews with Diabetic Kidney Disease Patients
  • Principal Investigator
    • A 16-week, Phase 2a, single-arm, multi-center, open-label study to evaluate the safety and efficacy of GSK1278863 after switching from recombinant human erythropoietin (rhEPO), in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are chronically hyporesponsive to rhEPO.
  • Principal Investigator
    • A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy (CREDENCE)
  • Principal Investigator
    • A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI 2690B Injection in Patients with Nephropathy Due to Diabetes
  • Principal Investigator
    • A Phase 2 Dose-ranging, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety and Tolerability of GS-4997 on Subjects with Stage 3 or Stage 4 Diabetic Kidney Disease
  • Sub Investigator
    • A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin™ (pyridoxamine dihydrochloride) in Subjects with Nephropathy Due to Type 2 Diabetes
  • Principal Investigator
    • A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
  • Principal Investigator
    • A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of dapradustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents
  • Principal Investigator
    • A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
  • Principal Investigator
    • Impact of Advance Care Planning Coaching for Patients with Chronic Kidney Disease (Making Your Wishes About You)
  • Principal Investigator
    • A 28-week, randomized, double-blind, placebo-controlled, parallel group, multi-center, study in recombinant human erythropoietin (rhEPO) naïve non-dialysis participants with anemia associated with chronic kidney disease to evaluate the efficacy, safety and effects on quality of life of daprodustat compared to placebo.
  • Principal Investigator
    • A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
  • Principal Investigator
    • A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease
  • Principal Investigator
    • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
  • Principal Investigator
    • A multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease (EMPA-CKD)
  • Principal Investigator
    • Global Kidney Patients Trial Network
  • Principal Investigator
    • A Phase IIb Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (Origin)

Publications

  • Robert Provenzano, Anatole Besarab, Chao H. Sun, Susan A Diamond, John H. Durham, Jose L. Cangiono, Joseph R. Aiello, James E. Novak, Tyson Lee, Robert Leong, Brian K. Roberts, Khalil G. Saikali, Stefan Hemmerich, Lynda A. Szczech, Kin-Hung Peony Yu, and Thomas B. Neff.  “Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.” Clinical Journal of American Society of Nephrology 11 (2016): 982-991.
Back To Top